Loading stock data…
NBP
$1.59+0.03 (+1.92%)
After Hours$1.60+0.01 (+0.63%)· Last close Jun 9
NovaBridge Biosciences, a biotechnology company, focuses on the research and development of immuno-oncology agents for the treatment of cancer in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
NovaBridge Biosciences in the Healthcare sector is trading at $1.59 with a market capitalization of $202M. Wall Street consensus targets $8.00 (3 analysts), implying a +403.1% move over the next 12 months. The stock is currently near its 52-week low of $1.52, remaining 54.7% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +403.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$1.59
Potential Downside
0%
Whystock Fair Value$1.59
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
NovaBridge Biosciences, a biotechnology company, focuses on the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. It is developi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$202.38M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.56
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-20.03%
Volume
Today's trading volume
401,606
Recent News
Companies Like NovaBridge Biosciences (NASDAQ:NBP) Can Afford To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Amazon downgraded, Roblox upgraded: Wall Street's top analyst calls
Amazon downgraded, Roblox upgraded: Wall Street's top analyst calls
Insider Spends US$5.1m Buying More Shares In NovaBridge Biosciences
NovaBridge Biosciences ( NASDAQ:NBP ) shareholders (or potential shareholders) will be happy to see that the Executive...
Is There An Opportunity With NovaBridge Biosciences' (NASDAQ:NBP) 40% Undervaluation?
Key Insights The projected fair value for NovaBridge Biosciences is US$6.70 based on 2 Stage Free Cash Flow to Equity...